000857533 001__ 857533
000857533 005__ 20240625095126.0
000857533 0247_ $$2doi$$a10.1124/mol.117.110064
000857533 0247_ $$2ISSN$$a0026-895X
000857533 0247_ $$2ISSN$$a0026-895x
000857533 0247_ $$2ISSN$$a1521-0111
000857533 0247_ $$2pmid$$apmid:29025967
000857533 0247_ $$2WOS$$aWOS:000415985000007
000857533 0247_ $$2altmetric$$aaltmetric:27519982
000857533 037__ $$aFZJ-2018-06524
000857533 082__ $$a610
000857533 1001_ $$0P:(DE-HGF)0$$aSchmidt, Axel$$b0$$eCorresponding author
000857533 245__ $$aDiminazene Is a Slow Pore Blocker of Acid-Sensing Ion Channel 1a (ASIC1a)
000857533 260__ $$aBethesda, Md.$$bASPET$$c2017
000857533 3367_ $$2DRIVER$$aarticle
000857533 3367_ $$2DataCite$$aOutput Types/Journal article
000857533 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1547622858_3400
000857533 3367_ $$2BibTeX$$aARTICLE
000857533 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000857533 3367_ $$00$$2EndNote$$aJournal Article
000857533 520__ $$aAcid-sensing ion channels (ASICs) are neuronal receptors for extracellular protons. They contribute to the excitatory postsynaptic current and to the detection of painful acidosis. Moreover, they are activated during peripheral inflammation and acidosis associated with various neuronal disorders, such as stroke and neuroinflammation, rendering them interesting drug targets. Diminazene aceturate is a small-molecule inhibitor of ASICs with a reported apparent affinity in the low micromolar range, making it an interesting lead compound. It was reported that diminazene accelerates desensitization of ASICs, which was, however, not explained mechanistically. Furthermore, a binding site in a groove of the extracellular domain was proposed but not experimentally verified. In this study, we revisited the mechanism of inhibition by diminazene and its binding site on ASIC1a, the ASIC subunit with the greatest importance in the central nervous system. We show that diminazene slowly blocks ASIC1a, leading to the apparent acceleration of desensitization and underestimating its potency; we show that diminazene indeed has a submicromolar potency at ASIC1a (IC50 0.3 μM). Moreover, we show that the inhibition is voltage-dependent and competes with that by amiloride, a pore blocker of ASICs. Finally, we identify by molecular docking a binding site in the ion pore that we confirm by site-directed mutagenesis. In summary, our results show that diminazene blocks ASIC1a by a slow open-channel block and suggest that diminazene is an interesting lead compound for high-affinity blockers of ASICs.
000857533 536__ $$0G:(DE-HGF)POF3-574$$a574 - Theory, modelling and simulation (POF3-574)$$cPOF3-574$$fPOF III$$x0
000857533 536__ $$0G:(DE-HGF)POF3-511$$a511 - Computational Science and Mathematical Methods (POF3-511)$$cPOF3-511$$fPOF III$$x1
000857533 588__ $$aDataset connected to CrossRef
000857533 7001_ $$0P:(DE-Juel1)145921$$aRossetti, Giulia$$b1$$ufzj
000857533 7001_ $$0P:(DE-HGF)0$$aJoussen, Sylvia$$b2
000857533 7001_ $$0P:(DE-HGF)0$$aGründer, Stefan$$b3$$eCorresponding author
000857533 773__ $$0PERI:(DE-600)1475030-2$$a10.1124/mol.117.110064$$gVol. 92, no. 6, p. 665 - 675$$n6$$p665 - 675$$tMolecular pharmacology$$v92$$x1521-0111$$y2017
000857533 8564_ $$uhttps://juser.fz-juelich.de/record/857533/files/665.full-1.pdf$$yRestricted
000857533 8564_ $$uhttps://juser.fz-juelich.de/record/857533/files/665.full-1.pdf?subformat=pdfa$$xpdfa$$yRestricted
000857533 909CO $$ooai:juser.fz-juelich.de:857533$$pVDB
000857533 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145921$$aForschungszentrum Jülich$$b1$$kFZJ
000857533 9131_ $$0G:(DE-HGF)POF3-574$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vTheory, modelling and simulation$$x0
000857533 9131_ $$0G:(DE-HGF)POF3-511$$1G:(DE-HGF)POF3-510$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lSupercomputing & Big Data$$vComputational Science and Mathematical Methods$$x1
000857533 9141_ $$y2018
000857533 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL PHARMACOL : 2017
000857533 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000857533 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000857533 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000857533 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000857533 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000857533 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000857533 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000857533 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000857533 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000857533 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000857533 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000857533 920__ $$lyes
000857533 9201_ $$0I:(DE-Juel1)IAS-5-20120330$$kIAS-5$$lComputational Biomedicine$$x0
000857533 9201_ $$0I:(DE-Juel1)JSC-20090406$$kJSC$$lJülich Supercomputing Center$$x1
000857533 980__ $$ajournal
000857533 980__ $$aVDB
000857533 980__ $$aI:(DE-Juel1)IAS-5-20120330
000857533 980__ $$aI:(DE-Juel1)JSC-20090406
000857533 980__ $$aUNRESTRICTED
000857533 981__ $$aI:(DE-Juel1)INM-9-20140121